Our participation in clinical trials
At NJ Retina, our physicians are actively involved in research as part of a host of multicentered clinical trials on new therapeutic approaches to retinal diseases. We have participated in a numerous national eye research studies, including:
Non-exudative “Dry” Age-Related Macular Degeneration (AMD) Studies
- Pfizer B1181003 Multiple doses of RN6G by infusion in patients with Geographic Atrophy secondary to Age-Related Macular Degeneration.
- Foresee Home Device Intended for the early detection of AMD.
Neovascular “Wet” Age-Related Macular Degeneration (AMD) Studies
- Lpath Nexus LT1009-Oph-003 4 monthly injections of iSonep given alone or in combination with Lucentis or Avastin in patients with wet AMD.
- OHR-002 Ophthalmic drops (Squalamine Lactate) in patients with wet AMD
- Alcon C-12-006 Injections of ESBA 1008 versus Eylea in subjects with wet AMD.
- VGFT-OD-0508 Intravitreal Injection of VEGF Trap in patients with wet AMD.
- VGFT-OD-0702 Phase 2 study of VEGF Trap injections in patients with wet AMD.
- VGFT-OD-0605 Phase 3 study of VEGF Trap injections in patients with wet AMD.
- Harbor Ranibizumab injections administered on monthly or as needed basis in patients with wet AMD.
- CATT Comparison Study of Lucentis versus Avastin in patients with wet AMD.
- Denali Comparison Study of Lucentis alone versus Lucentis plus photodynamic therapy in patients with wet AMD.
Diabetic Retinopathy Studies
Ongoing but not enrolling
- Rise Ranibizumab Injection in patients with clinically significant macular edema with center involvement secondary to Diabetes.
- VGFT-OD-1009 Intravitreal Injections of VEGF Trap-Eye in patients with Diabetic Macular Edema.
- Quark QRK202 2 part study. Part 1 – determines maximum tolerated dose of PF-04523655. Part 2 – Study of PF-04523655 used alone and in combination with ranibizumab versus ranibizumab alone in patients with Diabetic Macular Edema.
- VGFT-OD-0706 Phase 2 study of intravitreal injections of VEGF Trap-Eye in patients with Diabetic Macular Edema.
Retinal Vein Occlusion
- Allergan Comparing visual improvement and total number of intraocular injections in patients with macular edema following central retinal vein occlusion (CRVO) after initial treatment with Ozurdex or Avastin.
- CRUISE Study of Lucentis injections in patients with macular edema secondary to central retinal vein occlusion (CRVO).
- BRAVO Study of Lucentis injections in patients with macular edema secondary to branch retinal vein occlusion (BRVO).
- SCORE Study of Triamcinolone injections in patients with macular edema associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
- 32-007 Phase 3 study of Intravitreal injections of DE-109 in patients with active, non-infectious uveitis of the posterior segment of the eye.
Vitreomacular Adhesion Studies
Ongoing but not enrolling
- TG-MV-014 Study of Ocriplasmin in patients with symptomatic vitreomacular adhesion/(VMT) including macular hole.
- TG-MV-005 Ocriplasmin injection in patients with wet AMD/focal vitreomacular adhesion.
To learn more about these clinical trials, visit www.clinicaltrials.gov
For patients interested in enrolling in a clinical trial
Numerous clinical trials are available to appropriate NJ Retina patients for a variety of retinal conditions. If you are interested in determining if you might be eligible for a clinical trial, request an appointment at our office.